Page last updated: 2024-11-05

beta-farnesene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

beta-farnesene: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5317319
CHEBI ID39242
MeSH IDM0173355

Synonyms (28)

Synonym
1,6,10-dodecatriene, 7,11-dimethyl-3-methylene-, (z)-
(z)-.beta.-farnesene
beta-farnesene
(6z)-7,11-dimethyl-3-methylenedodeca-1,6,10-triene
(6z)-7,11-dimethyl-3-methylene-1,6,10-dodecatriene
beta-cis-farnesene
cis-beta-farnesene
28973-97-9
beta-(z)-farnesene
CHEBI:39242
(6z)-7,11-dimethyl-3-methylidenedodeca-1,6,10-triene
7,11-dimethyl-3-methylene-1,6,10-dodecatriene
(z)-7,11-dimethyl-3-methylene-1,6,10-dodecatriene
1,6,10-dodecatriene, 7,11-dimethyl-3-methylene-, (6z)-
beta-farnesene, (6z)-
g7f9bvf1ur ,
fema no. 3839, (6z)-beta-
unii-g7f9bvf1ur
.beta.-cis-farnesene
.beta.-farnesene, (6z)-
cis-.beta.-farnesene
fema no. 3839, (6z)-.beta.-
JSNRRGGBADWTMC-QINSGFPZSA-N
b-farnesene
Q27119785
(6z)-beta-farnesene
DTXSID101017764 ,
dtxcid801475947

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" We rationally designed a genetically defined Yarrowia lipolytica through recovery of L-leucine biosynthetic route, gene dosage optimization of β-farnesene synthase and disruption of the competition pathway."( Engineering the oleaginous yeast Yarrowia lipolytica for β-farnesene overproduction.
Fang, Y; Jiang, Y; Li, Y; Shi, T; Tong, Y; Wang, M; Yang, J; Yang, S; Zhang, J; Zhu, L, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
beta-farnesene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (124)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (5.65)18.2507
2000's23 (18.55)29.6817
2010's71 (57.26)24.3611
2020's23 (18.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (4.80%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other119 (95.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]